https://www.marketscreener.com/quote/stock/ASTELLAS-PHARMA-INC-6491262/news/Results-from-Astellas-Pivotal-Phase-3-SKYLIGHT-1-Study-of-Fezolinetant-for-Vasomotor-Symptoms-Due-to-43242049/?utm_source=telegram&utm_medium=social&utm_campaign=share